Member Info for goupplease

Yes this share will come good .
I love the bod wanting to solve the world health problems and give value ,
What a combination,
Okyo looks like going the same way , again caring

Okyo is being set up like Tiziana,
You are going to see great things
These guys know what makes a company

Nda ?

You can't take your eye off it .

To pick up today ,
Should open nice tomorrow (ihope)

I sold a batch this morning and bought in again on the drop.
Fingers crossed that bounce comes

I can see this really growing

Nfx owe us a run down of the last 12 months if no news by the 18th,
We need to know where we are .
A deal is on the cards

OKYO Pharma shares took a battering last week but investors might soon be on the receiving end of some welcome news.

Earlier this month, American eye surgeon Dr James Khodabakhsh joined the firm’s scientific advisory board as chairman. He is head of the Cedars-Sinai clinic in Beverly Hills, Los Angeles, which treats Hollywood stars and directors as well as popular singers.

Now City sources say the company - which is developing a treatment for dry eye - might see another high-profile healthcare scientist join in the next few weeks.

The new recruit is said to be the award-winning inventor of two drugs that generated sales of more than $11 billion.

I have waited over three years for this to turn the corner ,
Hope we progress this time .

Great price under 20p .
The smart money already here.
I think ackers has a chunk

Whimax atb.

It goes on the more I'm inclined to think they have a deal for StemprintER on the cards ,
I don't hold the tax excuse they are play for time .
It's nda

Have a plan .
They quickly took the placing .
It's not going to be overnight .
Afraid they are one step ahead

You must agree with me august is pivotal given everything.
Still time to stun us .
The agm might enlightenment

Imho it's big

OKYO Pharma shares took a battering last week but investors might soon be on the receiving end of some welcome news.

Earlier this month, American eye surgeon Dr James Khodabakhsh joined the firm’s scientific advisory board as chairman. He is head of the Cedars-Sinai clinic in Beverly Hills, Los Angeles, which treats Hollywood stars and directors as well as popular singers.

Now City sources say the company - which is developing a treatment for dry eye - might see another high-profile healthcare scientist join in the next few weeks.

The new recruit is said to be the award-winning inventor of two drugs that generated sales of more than $11 billion.

Anyone noticed how the #TILS de-ramping has stopped? Want to know why? Because those people have now taken their positions at a low price thanks to the holders that believed them and sold out. It’s the same thing every time.

Tils advisors are playing a clever game.
The split keeping people in for the placing .
Excuse "the tax situation " to tread water ,
Very clever people .

Next week is the week .
If CB has a deal nfx will launch it mon or Tues for agm news .
If no news your guess is as good as mine .
Pharma after pharma has released news and we were due in Q1 , no excuses anymore please